Patent intelligence · US
US 12077601
Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
Patent details — US 12077601
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 3, 2024
- Expiration
- Aug 29, 2044
- Applicant
- BANYAN BIOMARKERS, INC.
- Claims
- 20
- CPC classes
- A61P, A61P17/02, A61P21/04, A61P25/00
Quick answer
US 12077601 (Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods) is held by BANYAN BIOMARKERS, INC.. Status: granted. Granted Sep 3, 2024. Expires Aug 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BANYAN BIOMARKERS, INC.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61P, A61P17/02, A61P21/04, A61P25/00, A61P25/16, A61P25/28
More from BANYAN BIOMARKERS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 11885817
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11692030
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11598782
Biomarkers and methods for detection of seizures and epilepsy
granted -
US 11447500
Thienopyridine derivatives and pharmaceutical composition comprising same
granted -
US 11186873
Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)
granted -
US 11078298
Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
granted -
US 11008622
Biomarker for predicting sensitivity to EGFR-targeting agent, and use thereof
granted
Frequently asked questions
What is US patent 12077601?
US 12077601 (Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods) is held by BANYAN BIOMARKERS, INC.. Status: granted. Granted Sep 3, 2024. Expires Aug 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12077601?
BANYAN BIOMARKERS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 27 pharmaceutical patents for this assignee.
When does US 12077601 expire?
Our index shows an expiration date of Aug 29, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.